Publications by authors named "N A Fadeeva"
Little is known about the diversity and systematics of nematodes from intertidal sands of the Sea of Japan (East Sea). Here, nematodes of the rare genus Gairleanema and two new species of the family Xyalidae are described and illustrated. Metadesmolaimus innii sp.
View Article and Find Full Text PDFBackground: Prolgolimab is the first Russian PD-1 inhibitor approved for the first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was approved in two weight-based regimens of 1 mg/kg Q2W and 3 mg/kg Q3W, but because of re-evaluation of weight-based dosing paradigm, studying of a fixed-dose regimen was considered perspective.
Methods: We conducted a multicenter, single-arm, open-label efficacy, pharmacokinetics, and safety study to obtain data that would allow the approval of the new flat dosing regimen of prolgolimab in patients with previously untreated unresectable or metastatic melanoma (BCD-100-8/FLAT, NCT05783882).
Article Synopsis
- - The study aimed to assess the safety, tolerability, pharmacokinetics, and effectiveness of sasanlimab, a monoclonal antibody targeting PD-1, in treating participants with advanced cancers, including a focus on non-small-cell lung cancer.
- - An open-label design was used, with Phase Ib involving dose escalation and expansion in Asian participants, while Phase II included a global trial randomizing participants to receive either 300 mg every 4 weeks or 600 mg every 6 weeks.
- - Results indicated that Phase Ib had no dose-limiting toxicities and Phase II showed manageable grade 3 treatment-related adverse events, with confirmed response rates of 26.8% and 15.0%
Currently, there is an increase in the incidence of microscopic colitis. There are difficulties in diagnosing this disease due to the variability of histological signs, variability of morphological changes in the mucous membrane of the colon in different parts of the colon, and the combination in one patient of not only various forms of microscopic colitis, but also other intestinal diseases. The article describes the differential diagnosis, an example of its staging and successful treatment of various forms of microscopic colitis with budesonide (two clinical cases presented).
View Article and Find Full Text PDFBackground: BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to compare efficacy and safety of BCD-021 and reference bevacizumab in combination with paclitaxel and carboplatin in a first-line treatment of inoperable or advanced non-squamous non-small-cell lung cancer (NSCLC).
Methods: Patients with no previous treatment for advanced non-squamous NSCLC were randomly assigned 3:2 to BCD-021 or reference bevacizumab and were treated with bevacizumab + paclitaxel + carboplatin.